GTx, Inc. (Nasdaq: GTXI) today provided a Company update and reported financial results for the third quarter of 2013. The Company summarized additional analyses it has undertaken of the POWER1 and POWER2 clinical trials evaluating enobosarm 3 mg for the prevention and treatment of muscle wasting in patients with advanced non-small cell lung cancer (NSCLC). Using longitudinal continuous variable analyses, which was the statistical analysis pre-specified by the Company for submission of its data to the European regulatory authorities, enobosarm 3 mg demonstrated significant improvement in stair climb power, compared to placebo, in the POWER1 (platinum plus taxane) trial.
Help employers find you! Check out all the jobs and post your resume.
